Details der Publikation - A clinical trial to evaluate treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps)

A clinical trial to evaluate treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps) : A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa - SUNRISE

Medienart:	Klinische Studie

Erscheinungsjahr:	2022
Erschienen:	2022

Enthalten in:	WHO International Clinical Trials Registry Platform - (2022) vom: 02. Mai Zur Gesamtaufnahme - year:2022

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: hidradenitis suppurativa MedDRA version: 20.0Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Phase: Phase 3 Recruitment Status: Authorised-recruitment may be ongoing or finished Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 15-01-2019, Last updated: 2022-11-24

ICTRP ID:	EUCTR2018-002062-39-NL CAIN457M2302 2018-002062-39-GB

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	WHO008240590

Internformat


LEADER	01000caa a22002652 4500
001	WHO008240590
003	DE-627
005	20230425172229.0
007	cr uuu---uuuuu
008	220308s2022 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)WHO008240590
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2018-002062-39-NL
035			\|a (UBBS_Klinische_Studien_WHO)CAIN457M2302
035			\|a (UBBS_Klinische_Studien_WHO)2018-002062-39-GB
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a A clinical trial to evaluate treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps) \|b A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa - SUNRISE
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 15-01-2019, Last updated: 2022-11-24
650		4	\|a Medical Condition: hidradenitis suppurativa MedDRA version: 20.0Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 3
650		4	\|a Recruitment Status: Authorised-recruitment may be ongoing or finished
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2022) vom: 02. Mai
773	1	8	\|g year:2022 \|g day:02 \|g month:05
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002062-39 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2022 \|b 02 \|c 05

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände